ANTIVIRAL AGENTS

Targeting Human-Cytomegalovirus-Infected Cells by Redirecting T Cells Using an Anti-CD3/Anti-Glycoprotein B Bispecific Antibody

Weixu Meng,[a]* Aimin Tang,[b] Xiaohua Ye,[a] Xun Gui,[a] Leike Li,[a] Xuejun Fan,[a] Robbie D. Schultz,[a] Daniel C. Freed,[b] Sha Ha,[b] Dai Wang,[b] Ningyan Zhang,[a] Tong-Ming Fu,[b] Zhiqiang An[a]

[a]Texas Therapeutics Institute, Brown Foundation Institute of Molecular Medicine, University of Texas Health Science Center at Houston, Houston, Texas, USA

[b]Merck Research Laboratories, Merck & Co., Inc., Kenilworth, New Jersey, USA

in vitro.

Received 18 August 2017 **Returned for modification** 7 September 2017 **Accepted** 10 October 2017

Accepted manuscript posted online 16 October 2017

Citation Meng W, Tang A, Ye X, Gui X, Li L, Fan X, Schultz RD, Freed DC, Ha S, Wang D, Zhang N, Fu T-M, An Z. 2018. Targeting human-cytomegalovirus-infected cells by redirecting T cells using an anti-CD3/anti-glycoprotein B bispecific antibody. Antimicrob Agents Chemother 62:e01719-17. https://doi.org/10.1128/AAC.01719-17.

Address correspondence to Tong-Ming Fu, tong-ming_fu@merck.com, or Zhiqiang An, Zhiqiang.An@uth.tmc.edu.

* Present address: Weixu Meng, Division of Hematopoietic Stem Cell and Leukemia Research, Gehr Family Center for Leukemia Research, City of Hope, Duarte, California, USA.



[illegible] 1 [illegible] ( ) [illegible] (IGHV3-53*04), [illegible] 272.7, [illegible] 272.7). [illegible] 272.7 [illegible] 272.7 [illegible] 272.7 [illegible] 272.7 [illegible] ( ) [illegible] (*** $P < 0.001$). [illegible] ± [illegible] *, $P < 0.05$; **, $P < 0.01$; ***, $P < 0.001$.

[illegible] (17, 1). [illegible] 272.7 [illegible], 272.7, [illegible] 50% [illegible] (50) [illegible] 272.7, 3 e/ , [illegible] 50 [illegible] 272.7, 2 e/ (e.1).

[illegible] 272.7 [illegible] (, 10) , N -1 [illegible] 272.7 [illegible]


A
B
OKT3 scFv
Hu272.2 scFv
Reduced
Non-reduced
KD
100
M
1
2
3
4
5
6

[illegible]

[illegible] 50 [illegible] 17.2% [illegible] 60.7% [illegible] 5. % [illegible] (e. 2).

[illegible] 272.7 [illegible] 1.4 [illegible] 1.3, [illegible] 3 [illegible] (e. 2). [illegible] 3 [illegible] 3ε [illegible] 3 [illegible] e. 2 , [illegible] 272.7, [illegible]

[illegible] 4 [illegible] (N) [illegible] (e. 3). [illegible] 4 [illegible] (e. 1).

[illegible] *in vitro* [illegible] 71.1% [illegible] 2.6% [illegible] *in vitro.*

[illegible] (22). [illegible] (N). [illegible] N -1 [illegible] 10 [illegible] 200 [illegible] 0.1 μe/ (e. 3). [illegible]



1- 272.7 ( ) 4 ( ) 2 ( ) 25 ( ) 6 ( ) 107 ( ).

-α -γ 4,000 e/ (e.3). 25, 6 107 (e.3).



Merged
Light
GFP
A
B
C
HCMV+ ARPE19 cells
A'
B'
C'
D
D'
E
HCM
ARPE19

[illegible]

[illegible] (23, 26). [illegible] 3, ( ) [illegible]

[illegible] $p > 2\%$ [illegible] (13), [illegible] 3 [illegible] 272.7 [illegible] 3 [illegible] 17.2% [illegible] 60.7% [illegible] (e. 2). [illegible] $\sigma > 5\%$. [illegible] 1, 2, [illegible] 3 [illegible] 3 [illegible] (e. 4). [illegible] (e. 3). [illegible] 25, 6 [illegible] 107, [illegible] (e. 3, ,). [illegible] 0.1 μe/ [illegible] (e. 3). [illegible] (e. 4). [illegible] 10 [illegible] 20 [illegible] 1,000 × g [illegible] 10 [illegible] 00 × g [illegible] 30 [illegible] 10 [illegible]

[illegible]

[illegible] -0042-20030616).

1. [illegible] 24 52, 56. [illegible]/10.10 [illegible]/24.1.52.
2. [illegible] 200 [illegible] 5, 47. [illegible]/10.11 6/1743-422 -5-47.
3. [illegible] 2004. [illegible] 4, 611, 620. [illegible]/10.1111/[illegible].1600-6143.2004.003 2.
4. [illegible] 2010. [illegible] 200 [illegible] 10, 122, 1237. [illegible]/10.1111/[illegible].1600-6143.2010.03074.
5. [illegible] 2010. [illegible] 24, 413, 437. [illegible]/10.1016/[illegible].2010.01.001.
6. [illegible] 200 [illegible] 22, 162, 170. [illegible]/10.1111/[illegible].13 -0012.2007.00761.
7. [illegible] 67, 755, 757. [illegible]/10.10 7/00007 0-1 03150-00020.
8. [illegible] 2002. [illegible] 1 5, 20, 27. [illegible]/10.10 6/33 143.
9. [illegible] 2015. [illegible] 4, 35. [illegible]/10.103 [illegible].2015.5.
10. [illegible] 200 [illegible] 321, 74, 77. [illegible]/10.1126/[illegible].115 545.
11. [illegible] 2012. [illegible] 1, 1012, 1022. [illegible]/10.1016/[illegible].2012.01.022.
12. [illegible] 2001. [illegible] 24, 7, 15. [illegible]/10.1016/ 0022-175 (00)0033 -2.
13. [illegible] 16, 677, 6 1. [illegible]/10.103 / r07 -677.
14. [illegible] 6 [illegible] .617, 621. [illegible]/10.10 3/ [illegible] / .7.617.
15. [illegible] 17, 615, 620. [illegible]/10.10 7/000076 1-1 512000 -00012.
16. [illegible] 2013. [illegible] 110, 4 7, 5005. [illegible]/10.1073/[illegible].1316517110.
17. [illegible] 2017. [illegible] 41, 42. [illegible]/10.10 0/1 420 62.2017.12 302.
18. [illegible] 2012. [illegible] 12. [illegible]/10.1002/[illegible].23246.
19. [illegible] 7, 7 2.
20. [illegible] 206, 347, 34. [illegible]/10.1126/[illegible].31466.
21. [illegible] 2013. [illegible] 31, 753, 75. [illegible]/10.103 / [illegible].2621.
22. [illegible] 2000. [illegible] 40 [illegible] 1305, 310. [illegible]/10.103 /7 747.
23. [illegible] 2017. [illegible] 12 [illegible] 1, 01 57-16. [illegible]/10.112 / [illegible].01 57-16.
24. [illegible] 2015. [illegible] 11 4, 11. [illegible]/10.112 / [illegible].01701-15.
25. [illegible] 2016. [illegible] 7, 13627. [illegible]/10.103 / [illegible] 13627.
26. [illegible] 2012. [illegible] 12 -130-131 [illegible] 32, 1324, 1331. [illegible]/10.1007/[illegible] 10 75-012 - 73 -3.
27. [illegible] 2015. [illegible] 21, 4035, 403. [illegible]/10.115 /107 -0432. [illegible] -15-0612.
28. [illegible] .4723, 4727. [illegible]/10.1073/[illegible].11.4723.
29. [illegible] 2013. [illegible] 4, 00332-13. [illegible]/10.112 / [illegible]00332-13.
30. [illegible] 2015. [illegible] 67, 5, 106. [illegible]/10.1016/[illegible].2015.01.003.
31. [illegible] 2015. [illegible] 125, 4077, 40 0. [illegible]/10.1172/[illegible] 2314.
32. [illegible] 2012. [illegible] 5, 11, 1205. [illegible]/10.1002/[illegible].24237.
33. [illegible] 2013. [illegible]

110, 270, 275. rr . /10 .1073/ .121 17110.

34. N, N, . 1 0. 64 2 22, 2 31.

35. . 2011. 2 . 350, 356. rr . /10.1016/ .2011.0 .0 6.

36. . 2012. 30, 746, 7474. rr . /10.1016/ .2012.10.053.

37. . 2016. 362, 145. rr . /10.1126/ . 3 7.

3 . . 2012. 14, 116. rr . /10 .11 6/ . 3240.

3 . . 2015. 7, 707, 71 . rr . /10.10 0/1 420 62.2015.1051440.

40. N, N . 2006. 43, 763, 771. rr . /10.1016/ .2005.03.007.

41. . 2012, 3(3) 2(2) 1, 2, 3 . rr . /10.1002/ 4.10.

42. . 2011. 740, 33, 43. rr . /10.1007/ 7 -1-6177 -10 -6 6.

43. . 2012. 66, 36 3. rr . /10.37 1/36 3.

44. N . 2014. 405, 1 2, 1 . rr . /10.1016/ .2014.01 .012.